Department of Surgery, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain.
Digestive and Endocrine Surgery and Transplantation of Abdominal Organs, Biomedical Research Institute of Murcia (IMIB-Arrixaca), Murcia, Spain.
Front Immunol. 2021 Jul 26;12:672829. doi: 10.3389/fimmu.2021.672829. eCollection 2021.
Although proteomics has been employed in the study of several models of liver injury, proteomic methods have only recently been applied not only to biomarker discovery and validation but also to improve understanding of the molecular mechanisms involved in transplantation.
The study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology and the guidelines for performing systematic literature reviews in bioinformatics (BiSLR). The PubMed, ScienceDirect, and Scopus databases were searched for publications through April 2020. Proteomics studies designed to understand liver transplant outcomes, including ischemia-reperfusion injury (IRI), rejection, or operational tolerance in human or rat samples that applied methodologies for differential expression analysis were considered.
The analysis included 22 studies after application of the inclusion and exclusion criteria. Among the 497 proteins annotated, 68 were shared between species and 10 were shared between sample sources. Among the types of studies analyzed, IRI and rejection shared a higher number of proteins. The most enriched pathway for liver biopsy samples, IRI, and rejection was metabolism, compared to cytokine-cytokine receptor interactions for tolerance.
Proteomics is a promising technique to detect large numbers of proteins. However, our study shows that several technical issues such as the identification of proteoforms or the dynamic range of protein concentration in clinical samples hinder the successful identification of biomarkers in liver transplantation. In addition, there is a need to minimize the experimental variability between studies, increase the sample size and remove high-abundance plasma proteins.
尽管蛋白质组学已被应用于多种肝损伤模型的研究,但蛋白质组学方法最近才不仅被应用于生物标志物的发现和验证,而且还被应用于提高对移植相关分子机制的理解。
本研究遵循系统评价和荟萃分析的首选报告项目(PRISMA)方法和生物信息学中执行系统文献综述的指南(BiSLR)进行。通过 2020 年 4 月前的 PubMed、ScienceDirect 和 Scopus 数据库搜索了出版物。考虑了旨在了解肝移植结果(包括缺血再灌注损伤(IRI)、排斥或人类或大鼠样本中的操作耐受性)的蛋白质组学研究,这些研究应用了差异表达分析方法。
应用纳入和排除标准后,分析包括 22 项研究。在注释的 497 种蛋白质中,有 68 种在物种间共享,有 10 种在样本来源间共享。在分析的研究类型中,IRI 和排斥共享的蛋白质数量较多。与细胞因子-细胞因子受体相互作用相比,肝活检样本、IRI 和排斥的最丰富途径是代谢。
蛋白质组学是一种很有前途的检测大量蛋白质的技术。然而,我们的研究表明,一些技术问题,如蛋白质形式的鉴定或临床样本中蛋白质浓度的动态范围,阻碍了肝移植中生物标志物的成功鉴定。此外,需要减少研究之间的实验变异性,增加样本量并去除高丰度的血浆蛋白。